Y-R Yim1, K-E Lee1, D-J Park1, S-H Kim11, S-S Nah3, J H Lee4, S-K Kim5, Y-A Lee6, S-J Hong6, H-S Kim7, H-S Lee8, H A Kim9, C-I Joung10, S-H Kim11, S-S Lee1. 1. Department of Rheumatology, Chonnam National University Hospital & Medical School, Gwangju, Korea. 2. Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, Korea. 3. Department of Internal Medicine, College of Medicine, Soonchunhyang University, Cheonan, Korea. 4. Department of Internal Medicine, Maryknoll Medical Center, Busan, Korea. 5. Department of Internal Medicine, School of Medicine, Catholic University of Daegu, Korea. 6. Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea. 7. Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Korea. 8. Hanyang University College of Medicine and the Hospital for Rheumatic Diseases, Seoul, Korea. 9. Department of Allergy and Rheumatology, Ajou University Hospital, Ajou University School of Medicine, Suwon, Korea. 10. Department of Internal Medicine, Konyang University Medical School, Daejeon, Korea. 11. Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Korea.
Abstract
BACKGROUND: Patients with fibromyalgia (FM) exhibit significant clinical heterogeneity, in terms of physical, social and psychological functions, as well as therapeutic responses. Here, we examined FM patients in terms of pain, physical, social and psychological variables to identify clinical subgroups that may be predictive of treatment patterns. METHODS: A total of 313 FM patients were interviewed using a structured questionnaire that included sociodemographic data, current or past FM symptoms and current use of relevant medications. A K-means cluster analysis was conducted using variables reflecting tender points, the Fibromyalgia Impact Questionnaire, Beck Depression Inventory, State-Trait Anxiety Inventor and Social Support Scale. RESULTS: Four distinct clusters were identified in these patients. Group 1 was characterized by high pain levels, severe physical and mental impairment and low social support. Group 2 had moderate pain and physical impairment, mild mental impairment and moderate social support. Group 3 had moderate pain, low physical and moderate mental impairment and low social support. Group 4 had low pain levels, nearly normal physical and mental function and high social support. Group 1 was more often a current or past smoker, more likely to have a variety of symptoms, including swelling, cognitive dysfunction, dizziness, syncope, oesophageal dysmotility, dyspepsia, irritable bladder, vulvodynia and restless leg syndrome. CONCLUSIONS: We identified four subgroups of FM patients based on pain, physical, social and psychological function. These subgroups had different clinical symptoms and medication profiles, suggesting that FM may be better managed using a more comprehensive assessment of an individual patient's symptoms. SIGNIFICANCE: FM patients can be clustered into four distinct subgroups based on clinically measurable variables - pain, physical involvement, psychological function and social support. These subgroups had different clinical symptoms and medication profiles.
BACKGROUND:Patients with fibromyalgia (FM) exhibit significant clinical heterogeneity, in terms of physical, social and psychological functions, as well as therapeutic responses. Here, we examined FM patients in terms of pain, physical, social and psychological variables to identify clinical subgroups that may be predictive of treatment patterns. METHODS: A total of 313 FM patients were interviewed using a structured questionnaire that included sociodemographic data, current or past FM symptoms and current use of relevant medications. A K-means cluster analysis was conducted using variables reflecting tender points, the Fibromyalgia Impact Questionnaire, Beck Depression Inventory, State-Trait Anxiety Inventor and Social Support Scale. RESULTS: Four distinct clusters were identified in these patients. Group 1 was characterized by high pain levels, severe physical and mental impairment and low social support. Group 2 had moderate pain and physical impairment, mild mental impairment and moderate social support. Group 3 had moderate pain, low physical and moderate mental impairment and low social support. Group 4 had low pain levels, nearly normal physical and mental function and high social support. Group 1 was more often a current or past smoker, more likely to have a variety of symptoms, including swelling, cognitive dysfunction, dizziness, syncope, oesophageal dysmotility, dyspepsia, irritable bladder, vulvodynia and restless leg syndrome. CONCLUSIONS: We identified four subgroups of FM patients based on pain, physical, social and psychological function. These subgroups had different clinical symptoms and medication profiles, suggesting that FM may be better managed using a more comprehensive assessment of an individual patient's symptoms. SIGNIFICANCE: FM patients can be clustered into four distinct subgroups based on clinically measurable variables - pain, physical involvement, psychological function and social support. These subgroups had different clinical symptoms and medication profiles.
Authors: Katherine Hadlandsmyth; Dana L Dailey; Barbara A Rakel; M Bridget Zimmerman; Carol Gt Vance; Ericka N Merriwether; Ruth L Chimenti; Katharine M Geasland; Leslie J Crofford; Kathleen A Sluka Journal: J Health Psychol Date: 2017-10-27
Authors: Susmita Kashikar-Zuck; Natoshia Cunningham; James Peugh; William R Black; Sarah Nelson; Anne M Lynch-Jordan; Megan Pfeiffer; Susan T Tran; Tracy V Ting; Lesley M Arnold; Adam Carle; Jennie Noll; Scott W Powers; Daniel J Lovell Journal: Pain Date: 2019-02 Impact factor: 7.926
Authors: Sheila M Gaynor; Andrey Bortsov; Eric Bair; Roger B Fillingim; Joel D Greenspan; Richard Ohrbach; Luda Diatchenko; Andrea Nackley; Inna E Tchivileva; William Whitehead; Aurelio A Alonso; Thomas E Buchheit; Richard L Boortz-Marx; Wolfgang Liedtke; Jongbae J Park; William Maixner; Shad B Smith Journal: Pain Date: 2021-05-01 Impact factor: 7.926
Authors: Fred Davis; Mark Gostine; Bradley Roberts; Rebecca Risko; Joseph C Cappelleri; Alesia Sadosky Journal: J Pain Res Date: 2018-10-23 Impact factor: 3.133
Authors: Patricia Catala; Sofia Lopez-Roig; Carmen Ecija; Carlos Suso-Ribera; Cecilia Peñacoba Puente Journal: Rheumatol Int Date: 2020-10-13 Impact factor: 2.631
Authors: Jesús Montero-Marín; Mayte Navarro-Gil; Marta Puebla-Guedea; Juan V Luciano; William Van Gordon; Edo Shonin; Javier García-Campayo Journal: Front Psychiatry Date: 2018-01-16 Impact factor: 4.157